Sector News

Bristol-Myers buys rights to acquire fibrosis drug developer

September 1, 2015
Life sciences

Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring.

The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis.

PRM-151 is undergoing trials as a treatment for the lung condition, idiopathic pulmonary fibrosis, and a form of blood disorder called myelofibrosis.

Myelofibrosis, a condition that affects the bone marrow, is classified as a rare disease by the U.S. National Institutes of Health.

The only drug approved by the U.S. Food and Drug Administration to treat myelofibrosis is Incyte Corp’s Jakafi, which raked in about $258 million in sales for the six months ended June 30.

Bristol-Myers has four experimental fibrosis drugs in its pipeline, two of them in mid-stage and two in early studies.

Promedior’s mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.

Lexington, Massachusetts-based Promedior is backed by healthcare investors including British drugmaker Shire Plc.

Bristol-Myers said rights to buy Promedior could be exercised after the completion of either of the studies.

The deal includes an upfront cash payment of $150 million for the right to acquire Promedior.

Bristol-Myers’ shares were little changed at $60.95 in early trading on the New York Stock Exchange.

(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach